Edition:
India

Fate Therapeutics Says NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies, Solid Tumors


Monday, 12 Nov 2018 

Nov 12 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION CLINICAL DATA OF FATE-NK100 AND PROVIDES REGULATORY UPDATE ON LANDMARK IND APPLICATION FOR FT500.NK100 SHOWS CLINICAL BENEFIT IN TREATING ADVANCED HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS.SUBMITTED DATA TO FDA DEMONSTRATING FT500 MASTER IPSC BANK IS FREE OF ADVENTITIOUS AGENTS. 

Company Quote

19.12
1.29 +7.24%
17 Jun 2019